Postpartum haemorrhage (PPH) remains a leading cause of maternal morbidity and mortality. 1 Fibrinogen is an essential endogenous component of haemostasis, 2 and its plasma concentration increases during pregnancy. 3 Observational studies of patients with PPH indicate that a low fibrinogen concentration in the early phase of PPH is associated with excessive subsequent bleeding and blood transfusion. 4 -7 Fibrinogen concentrate is widely used to correct acquired hypofibrinogenaemia, but evidence is lacking regarding the efficacy of this treatment. 8 9 We aimed to assess the efficacy of a pre-emptive treatment with fibrinogen concentrate in patients with PPH, 10 and hypothesized that treatment with fibrinogen concentrate reduces the need for red blood cell (RBC) transfusion up to 6 weeks postpartum.
Methods

Ethical approval
The Danish National Committee on health research ethics approved this trial (protocol number 1002168/H-3-2010-004).
Written informed consent was obtained from all subjects entering the trial.
Randomization and masking
This trial was investigator-initiated, without any financial or academic involvement from the manufacturers of fibrinogen concentrate. We designed a multicentre, double-blinded, centre-stratified trial with 1:1 parallel groups and used computer-generated allocation and blocks-of-four randomization (done by third party before study commencement). This was concealed by envelopes. When including a subject, an envelope was collected and the content decided/randomized the subject to either intervention or placebo. The stratification by centres implies that within each centre the number of envelopes with intervention or placebo was balanced, and an excess of envelopes was available at all times. We randomly assigned patients with primary PPH regardless of mode of delivery to early pre-emptive treatment with a single i.v. dose of fibrinogen concentrate (RiaSTAP&; CSL Behring, Marburg, Germany) or placebo (isotonic saline) administered by the anaesthetist on arrival in the operating theatre. Subjects received written project information during pregnancy. They were invited to participate and informed consent was sought by the attending anaesthetist at the pre-anaesthetic evaluation before Caesarean section, when labour epidural was performed, or following vaginal delivery with bleeding. In order to secure blinding, we used an anaesthetist doctor or nurse not involved in the treatment of the patient to carry out the randomization and dispensation. Subjects, care providers, outcome assessors, and the statistician were blinded to allocation. Opaque syringes (yellow coloured) were used to disguise the content of the study infusion. We assessed physician and subject blinding. No interim analysis was performed. The FIB-PPH (FIBrinogen concentrate as initial treatment for PostPartum Haemorrhage) trial was conducted between May 30, 2011 and July 11, 2013 in four university-affiliated public tertiary care hospitals in the Capital Region of Copenhagen, Denmark (Rigshospitalet, Hvidovre Hospital, Herlev Hospital, and Hillerød Hospital). Each centre had 3500 -7000 deliveries yr 21 , which represents 99% of all deliveries in this region (1% are home deliveries). The trial protocol, including planned statistical analyses, has been published elsewhere. 10 
Subjects
All subjects entering the trial were randomized once the following PPH inclusion criteria were met: (i) age ≥18 yr; and (ii) PPH defined as bleeding from uterus and/or birth canal within 24 h postpartum. Additional inclusion criteria were Caesarean section with an estimated perioperative blood loss .1 litre or vaginal delivery with either estimated blood loss .0.5 litre and intended manual removal of placenta or estimated blood loss .1 litre and intended manual exploration of the uterus because of continuous bleeding after delivery of the placenta (Fig. 1 ). All hospitals in the Capital Region of Denmark follow our national guidelines for treatment of PPH, including treatment with oxytocin. Blood loss up to 0.5 litre was assessed by visual inspection of the absorbent delivery pad, and thereafter determined by weighing of drapes and pads as described in the national guidelines. 11 Exclusion criteria were as follows:
(i) known inherited coagulation deficiencies; (ii) antenatal anti-thrombotic treatment; (iii) pre-pregnancy weight ,45 kg; or (iv) refusal to receive blood transfusion.
Intervention and placebo
The fibrinogen group received a fixed dose of 2 g of fibrinogen concentrate dispensed in 100 ml sterile water. The placebo group received 100 ml of isotonic saline. This was applied in a pragmatic early pre-emptive treatment regimen, giving a fixed dose to all subjects irrespective of body weight and not guided by measurement of fibrinogen concentration or other haemostatic measures. The solution was dispensed using syringepump infusion over 20 min according to the manufacturer's recommendation. 12 Additional interventions, including the use of tranexamic acid and i.v. fluids, were at the discretion of the attending physician supported by regional guidelines. 13 The anaesthetists following study drug administration and subjects at the 6 week follow-up were asked to evaluate the blinding.
Haemostatic monitoring and adverse events
Blood samples were taken before intervention (baseline) and 15 min, 4 h, and 24 h after infusion of the study drug. Specially trained nurses obtained the samples and assessed fluid, transfusion status, and adverse events at 4 and 24 h after intervention. The haemostatic monitoring has been described previously. 10 Data on blood transfusions were retrieved from charts and validated in the Blood Bank Database. We approached all subjects 6 weeks postpartum by telephone and asked about contact with general physicians or hospitals. Charts were assessed for readmissions and thromboembolic events.
Outcomes
The primary outcome was RBC transfusion during a 6 week follow-up period postpartum. 
Statistical analyses
We calculated that 245 subjects were needed to show a reduction in relative risk of 33% with a power of 80%, a two-sided type I error of 0.05, and up to 15% dropouts. We estimated that fibrinogen would reduce the proportion of subjects receiving postpartum transfusion from 57 to 38%. The estimate of the proportion of subjects in need of RBC transfusion was based on approximately 1% (range 0.31 -2.7%) 10 of parturients receiving RBC transfusion and 1.75% developing severe PPH (defined by a blood loss .1 litre). 15 Analyses of outcomes were performed before breakage of the randomization code.
The intention-to-treat (ITT) population was used for analyses, including all randomized subjects with consent to participate regardless of exclusion criteria or having received the wrong dose. In the per-protocol analysis, we omitted those who met exclusion criteria or who did not receive the full dose. Estimates of treatment effect were compared for the pre-stated subgroups. 10 Unadjusted x 2 tests for binary outcome measures and Student's t-test or Wilcoxon rank-sum test were used for continuous measures. Results are presented as the relative risk with a 95% confidence interval (CI), mean (SD), and P-value. Logistic regression was used to assess association with baseline variables, and we present adjusted analysis with odds ratio (OR), 95% CI, and P-value. Explanatory post hoc analyses using logistic regression were performed, including factors with baseline imbalance, statistical interaction, or suspected additional confounding effect. The stratification variable (centre) and baseline variables that were significant in the univariate analysis were included in the adjusted analyses. All analyses were performed with the use of R statistical software, version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria).
A two-sided P-value of ,0.05 was considered statistically significant. Changes in fibrinogen and Hb during the first 24 h after study drug infusion were compared between groups using longitudinal analysis (mixed-effect model).
Role of the funding source
This trial was funded by independent funds and without any financial or academic involvement from the manufacturer of fibrinogen concentrate. The funding source had no involvement. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Study population
A total of 249 subjects were randomized, and 244 were available for final analysis on transfusion requirements up to 6 weeks; 123 in the fibrinogen group and 121 in the placebo group (Fig. 1 ). All 244 subjects had severe PPH, with a mean blood loss of 1.5 litre, and 10% with a systolic arterial pressure ,100 mm Hg at inclusion. The distribution of subjects by inclusion criteria was as follows: exploration of the uterine cavity after vaginal delivery [n¼123 (50%)], Caesarean section and blood loss .1 litre [n¼ 40 (16%)], and decision on manual removal of a retained placenta with initial blood loss ≥0.5 litre [n ¼81 (33%); Table 1 ]. Three subjects (all assigned to the fibrinogen group) had exclusion criteria discovered following intervention; one with Factor Leiden V mutation, and two with antithrombotic treatment during pregnancy. Baseline characteristics are presented in (Fig. 2) . Additional longitudinal analysis of Hb concentrations showed a significant decrease during the first 24 h compared with baseline, but with no difference between the fibrinogen group and the placebo group (details of additional treatment and fibrinogen concentration can be found in Fig. 2 and Supplementary data). 
Continued
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Blinding
A total of 220 (94%) of the 235 anaesthetists who evaluated blinding following intervention had no idea of which treatment was provided, but nine (4%) had noticed a small amount of foam in the tubes, indicating fibrinogen concentrate. Besides the deliberate unblinding of one subject (placebo) who developed universal urticaria 2 days after the intervention, no subjects had discovered their allocation. Based on recovery or experience of adverse events, 98 (41%) patients felt they knew their allocation group. However, the same proportion believed they had received fibrinogen in both groups (Supplementary data). Sensitivity analysis of complete blinding did not affect estimates of treatment effect (Supplementary data).
Discussion
In this investigator-initiated, randomized, double-blinded, multicentre trial, we found no reduction in RBC transfusion during a 6 week follow-up period postpartum following administration of 2 g of fibrinogen concentrate. The FIB-PPH trial is the largest randomized controlled trial investigating fibrinogen concentrate. 8 It is investigator initiated, the first trial in obstetric patients, and the only trial Fibrinogen for postpartum haemorrhage where subjects were randomized in an emergency setting. Only two of six previous randomized controlled trials investigating fibrinogen concentrate blinded subjects and clinicians, 8 but in this trial we successfully blinded most clinicians and all the subjects. The pragmatic multicentre trial set-up and our few exclusion criteria strengthen the external validity, with the randomized design reducing selection and performance bias. However, our results are limited by the wide confidence intervals on the primary result caused by the lower than expected proportion of included subjects in need of RBC transfusion. 10 The primary reason for this is probably the inability to include subjects with massive and rapid bleeding because of the need for informed written consent obtained in the emergency setting. As a result of our early pre-emptive treatment regimen, inclusion was not restricted to patients with hypofibrinogenaemia, and fibrinogen dose was not adjusted to body weight or haemostatic measures. Included patients should be able to give informed consent. The median time from screening to inclusion was ,1 h. This reflects that most subjects delivered vaginally, not by planned Caesarean section, and therefore consent was obtained when epidural anaesthesia was provided or when PPH was diagnosed. The use of antepartum written information and obtaining final consent was in accordance with the recommendations of Royal College of Obstetricians and Gynaecologists. 16 In 46 screened patients, it was impossible to obtain consent. Not being able to include cases with severe and rapid PPH is probably reflected in the low number of subjects with initial hypofibrinogenaemia and a lower incidence of RBC transfusion than expected. The incidence of venous thromboembolic events in our population is estimated to be 0.7 -2 per 1000 pregnancies. 17 The sample of 244 subjects is insufficient to assess the risk of thrombosis associated with fibrinogen concentrate, but no symptomatic thromboembolic events were seen at the 6 week follow-up. A Cochrane review showed that fibrinogen concentrate in bleeding patients was associated with a 53% reduction in RBC transfusion, 8 but it included only 208 patients, mainly undergoing cardiac surgery. The fibrinogen concentration was ,2 g litre 21 at inclusion, except for one study investigating preoperative prophylactic treatment of patients with a mean preoperative fibrinogen of 2.9 g litre 21 .
18 Few of our subjects received colloids, and given that fibrinogen concentrate can alleviate the haemostatic impairment of synthetic colloids (e.g. hydroxyethyl starch), 19 this could explain the lack of efficacy in our trial compared with trials in the Cochrane review. Tranexamic acid reduces fibrinolysis and protects endogenous fibrinogen. Tranexamic acid was given to 31% of subjects before intervention and few had a fibrinogen ,2 g litre 21 at inclusion, and thus they might have had a lesser degree of initial coagulopathy compared with patients after cardiopulmonary bypass. 20 A total of 38% of subjects received tranexamic acid within 24 h, and even if our adjusted analysis did not detect a direct influence on blood transfusion it might be that co-administration of tranexamic acid would have given another result. 9 As other co-interventions can dilute fibrinogen and thus affect the validity of our findings, we have provided detailed description of co-interventions and aimed to reduce their impact on our findings. The change in fibrinogen before and after study drug administration is not only a result of the study treatment, but mainly because of ongoing dilution by fluids (mainly crystalloids) and consumption (e.g. fibrinogen concentration decreased by 0.3 g litre 21 in the placebo group). Fibrinogen concentration was 0.4 g litre 21 higher in the fibrinogen group following administration of study drug compared with placebo. The fibrinogen increment of 0.1 g litre 21 obtained in the fibrinogen group shows that 2 g of fibrinogen concentrate was enough to avoid a decrease, and even to restore and increase fibrinogen concentration. In the study by Charbit and colleagues, 4 10% of patients with PPH after manual exploration of the uterine cavity requiring i.v. prostaglandin administration had an initial fibrinogen concentration ,2 g litre 21 . Unfortunately, no data were presented on blood loss or resuscitation with crystalloids or colloids. In our study, fewer subjects had an initial fibrinogen concentration ,2 g litre 21 , fewer received fresh frozen plasma and were in need of haemostatic intervention, but an equal proportion Fibrinogen for postpartum haemorrhage presented with hypovolaemia and a higher rate of RBC transfusion within 24 h. Charbit and colleagues 4 reported a longer delay from inclusion to baseline blood sampling in those patients who developed the most severe course of bleeding; 4 this delay might be associated with increased dilution, loss of blood, and loss of fibrinogen such that the initial concentration of fibrinogen may be a surrogate marker of blood loss. 21 This corresponds to our finding that the risk of postpartum transfusion was lower in those with increased fibrinogen concentration following intervention, but this effect disappeared after adequate adjustments for dilution, blood loss, tranexamic acid use, and the cause of PPH. Fibrinogen concentrate is increasingly used in acquired hypofibrinogenaemia associated with bleeding and as pre-emptive treatment in PPH. 22 Some even recommend 2-4 g of fibrinogen concentrate in the case of 1.5 litre bleeding. 23 However, this represents off-label use in most countries. 24 Several observational studies have reported on the use of fibrinogen concentrate in obstetrical haemorrhage; 25 -30 in patients with low fibrinogen (1-1.5 g litre
21
) and co-administration of multiple transfusions, including fresh frozen plasma. These studies are based on retrospective chart evaluation, without appropriate control groups, and are associated with a high risk of selection bias, especially the risk of confounding by indication. In addition, most trials investigating fibrinogen concentrate have been sponsored by the manufacturer of fibrinogen concentrate. 8 Based on our findings, further pre-emptive use of fibrinogen concentrate in PPH 22 is not justified. Future studies on PPH should investigate the impact of goal-directed fibrinogen substitution in patients with hypofibrinogenaemia and apply a method of consent that allows for inclusion of patients with rapid and massive bleeding.
In conclusion, we found no evidence for the use of preemptive treatment with fibrinogen concentrate for severe postpartum haemorrhage in patients with normofibrinogenaemia.
Supplementary material
Supplementary data are available at British Journal of Anaesthesia online.
